Skip to main content
Equibles
GH logo

GH

Guardant Health, Inc.
$156.17 -6.75 (-4.14%) At close · Jul 8
Market Cap
$22.53B
Shares
132,599,929

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$156.17 Open$159.29 Day$155.75–160.90 52W$40.35–174.08 Avg vol 30d3.1M Short int13.1M · 9.9% float · 6.4d Short vol45% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Equibles Rating blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +57%
above
Price vs 50-day avg +29%
above
RSI (14) 63
neutral
MACD trend Positive
52-week position 87%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +25%
trailing
6-month return +46%
trailing
YTD return +53%
this year
Relative strength +39%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $121 › 200d $99 — 50d above 200d
Institutional flow Accumulating
14 of 488 funds reported for Jun 30 · net +2.9K sh shares · +1 new
Insider flow Distributing
Net -$52.0M over 90 days · 92% sells
Short interest Falling
9.87% of float · ▼ -0.9% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
488 holders — near 3-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Weak
Revenue growth +33%
Y/Y
EPS growth +7%
Y/Y
Free cash flow $-233.1M
Balance sheet $1.1B
net debt
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −33%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 6, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Guidance & track record
      Latest guidance · from the 8-K filed May 7, 2026
      full year 2026
      Total revenue Initiated $1.3B – $1.32B
      prior FY $982.02M midpoint +33.4% Y/Y
      Non-GAAP gross margin Non-GAAP Initiated 64% – 65%
      Total non-GAAP operating expenses Non-GAAP Initiated $1.05B – $1.07B
      2026
      Oncology revenue growth Initiated 28% – 29%
      Oncology volume growth Initiated at least 35%
      Screening revenue Initiated $186M – $198M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +57% Bullish
      Price vs 50-day avg
      +29% Bullish
      RSI (14)
      63 Neutral
      MACD trend
      Positive Bullish
      52-week position
      87% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $121 › 200d $99 — 50d above 200d
      Institutional flow Accumulating
      14 of 488 funds reported for Jun 30 · net +2.9K sh shares · +1 new
      Insider flow Distributing
      Net -$52.0M over 90 days · 92% sells
      Short interest Falling
      9.87% of float · ▼ -0.9% MoM · 6.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      488 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $40 Now $156 · 87% 52-wk high $174
      vs 200-day avg +57% vs 50-day avg +29%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Adjusted EBITDA loss non-GAAP -$58.9M Q1 2026 —
      CDx approvals 26 Q1 2026 call —
      data repository patient samples 1M Q1 2026 call —
      DTC campaign impressions 1B Q1 2026 call —
      EMR-connected HCPs via Quest 650,000 Q1 2026 call —
      epigenetic profiles 500,000 Q1 2026 call —
      Guardant360 Liquid volume year-over-year growth 30% Q1 2026 call —
      HCPs targeted by March campaign 200,000 Q1 2026 call —
      Oncology revenue year-over-year growth 36% Q1 2026 call —
      Oncology test volume year-over-year growth 47% Q1 2026 call —
      Oncology test volumes 86,000 Q1 2026 call —
      phlebotomists in network 40,000 Q1 2026 call —
      Quest patient service centers 8,000 Q1 2026 call —
      Shield adherence rate 90% Q1 2026 call —
      Shield testing volume 44,000 Q1 2026 call —
      trailing 12-month revenue $1B Q1 2026 call —
      Adjusted EBITDA non-GAAP -$64.9M Q4 2025 —
      Free cash flow -$233M Full Year FY2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GH
      Guardant Health, Inc.
      this stock
      		$22.53B +52.9% +32.9% — 9.9%
      TMO
      Thermo Fisher Scientific Inc.
      		 $189.58B -11.9% +0.4% 28.0 1.2%
      DHR
      Danaher Corp /De/
      		 $135.02B -16.3% +8.5% 36.8 1.6%
      IDXX
      Idexx Laboratories Inc /De
      		 $43.83B -17.9% +10.4% 40.9 2.7%
      NTRA
      Natera, Inc.
      		 $40.33B +19.8% -2.8% — 3.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      489
      % held
      100.6%
      Reported
      14 of 488
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      542
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      13.1M
      Days to cover
      6.4d
      Change
      -120.0K sh
      View
      Short Volume
      Short vol %
      45%
      As of
      Jul 8, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      19
      Value
      $2.5K
      As of
      Jun 11, 2026
      View
      Off-Exchange
      Off-exchange %
      44.3%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$52.0M
      Buyers / Sellers
      1 / 11
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Sheldon Whitehouse
      Amount
      $1.0K–$15.0K
      Traded
      Nov 21, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $982.0M
      Net income (FY)
      $-416.3M
      EPS diluted
      $-3.32
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $660.0K
      Shares
      4.0K
      Filed
      Jul 1, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 17, 2026
      View
      Investor Relations
      Latest news
      UnitedHealth Group Now Covers Gua…
      Published
      Jul 1, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      GH +4.1% +25.1% +46.1% +4.1% +52.9%
      SPY -0.2% +0.8% +7.4% -0.2% +9.3%
      vs SPY +4.3% +24.2% +38.7% +4.3% +43.6%
      Key facts CIK 1576280 CUSIP 40131M109 13F (30d) 16 filings 15 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)